Skip to main content
. 2018 Jul 17;4:17. doi: 10.1186/s40780-018-0113-3

Table 4.

Numbers of the questions from patients regarding DAAs treatment

Type of questions Number (%)
Adverse drug events 577 (53.8%)
Drug interaction a 205 (19.1%)
Management in the event of a missed dose of DAAs 57 ( 5.3%)
Others 233 (21.8%)
TOTAL 1,072 (100%)

DAAs Direct-acting antivirals

a These included questions according to drug-drug (152 cases), drug-supplement (32 cases), and drug-food (21 cases) interactions